AxioMx this week launched its new custom recombinant antibody discovery and development services, which include epitope mapping and antigen design as well as antibody screening, optimization, and production.
The company's proprietary phage display libraries and "rapid liquid" screening and affinity maturation methods enable it to produce monoclonal antibodies in as little as eight weeks, it said.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
